Experience of using secukinumab in the treatmentof patients with psoriasis
Psoriasis is one of the most common chronic dermatoses. In recent years, there has been an increase in the number of patients with severe, disabling forms of dermatosis, resistant to the therapy. The disease significantly reduces the quality of life, disrupts patients' ability to work, which de...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2021-11-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839591451682406400 |
|---|---|
| author | N. V. Zilberberg Ya. V. Kascheeva M. M. Kokhan |
| author_facet | N. V. Zilberberg Ya. V. Kascheeva M. M. Kokhan |
| author_sort | N. V. Zilberberg |
| collection | DOAJ |
| description | Psoriasis is one of the most common chronic dermatoses. In recent years, there has been an increase in the number of patients with severe, disabling forms of dermatosis, resistant to the therapy. The disease significantly reduces the quality of life, disrupts patients' ability to work, which defines dermatosis as socially significant and entails the need to improve therapeutic approaches. Psoriatic arthritis, or artopathic psoriasis, is a chronic inflammatory disease of the joints, spine and enthesis, which can be observed in patients with psoriasis. The article presents the main current information about the pathogenesis of psoriasis and psoriatic arthritis with an emphasis on the immunopathological aspects of the development of diseases and the rationality for the use of the proinflammatory cytokine inhibitor interleukin-17 in the therapy. Modern advances in understanding the mechanism of development of psoriasis and psoriatic arthritis served as a rationale for the creation of a group of innovative targeted drugs – genetically engineered biological drugs, the mechanism of action of which is to block certain cytokines, both circulating in the systemic circulation and located in the inflamed tissue of psoriatic plaques or joint. In the article brief information about the results of clinical trials of secukinumab is provided; clinical examples highlight experience of effective treatment of patients with psoriasis and psoriatic arthritis. It has been shown that early cessation of the progression of the inflammatory process in psoriasis through biological therapy with secukinumab leads to a decrease in skin symptoms, a decrease in pain and subclinical inflammation in the joints. The high efficacy and safety of the drug allows complete control of the disease and improve the quality of life in patients. |
| format | Article |
| id | doaj-art-9a8af9de78b749b08d6942baf3dd070b |
| institution | Matheson Library |
| issn | 1560-5175 2687-1181 |
| language | Russian |
| publishDate | 2021-11-01 |
| publisher | Open Systems Publication |
| record_format | Article |
| series | Лечащий Врач |
| spelling | doaj-art-9a8af9de78b749b08d6942baf3dd070b2025-08-03T13:02:53ZrusOpen Systems PublicationЛечащий Врач1560-51752687-11812021-11-01010414510.51793/OS.2021.24.10.007822Experience of using secukinumab in the treatmentof patients with psoriasisN. V. Zilberberg0Ya. V. Kascheeva1M. M. Kokhan2Ural Research Institute of Dermatology, Venereology and ImmunopathologyUral Research Institute of Dermatology, Venereology and ImmunopathologyUral Research Institute of Dermatology, Venereology and ImmunopathologyPsoriasis is one of the most common chronic dermatoses. In recent years, there has been an increase in the number of patients with severe, disabling forms of dermatosis, resistant to the therapy. The disease significantly reduces the quality of life, disrupts patients' ability to work, which defines dermatosis as socially significant and entails the need to improve therapeutic approaches. Psoriatic arthritis, or artopathic psoriasis, is a chronic inflammatory disease of the joints, spine and enthesis, which can be observed in patients with psoriasis. The article presents the main current information about the pathogenesis of psoriasis and psoriatic arthritis with an emphasis on the immunopathological aspects of the development of diseases and the rationality for the use of the proinflammatory cytokine inhibitor interleukin-17 in the therapy. Modern advances in understanding the mechanism of development of psoriasis and psoriatic arthritis served as a rationale for the creation of a group of innovative targeted drugs – genetically engineered biological drugs, the mechanism of action of which is to block certain cytokines, both circulating in the systemic circulation and located in the inflamed tissue of psoriatic plaques or joint. In the article brief information about the results of clinical trials of secukinumab is provided; clinical examples highlight experience of effective treatment of patients with psoriasis and psoriatic arthritis. It has been shown that early cessation of the progression of the inflammatory process in psoriasis through biological therapy with secukinumab leads to a decrease in skin symptoms, a decrease in pain and subclinical inflammation in the joints. The high efficacy and safety of the drug allows complete control of the disease and improve the quality of life in patients.https://journal.lvrach.ru/jour/article/view/824psoriasispsoriatic arthritistherapygenetically engineered biological drugssecukinumab |
| spellingShingle | N. V. Zilberberg Ya. V. Kascheeva M. M. Kokhan Experience of using secukinumab in the treatmentof patients with psoriasis Лечащий Врач psoriasis psoriatic arthritis therapy genetically engineered biological drugs secukinumab |
| title | Experience of using secukinumab in the treatmentof patients with psoriasis |
| title_full | Experience of using secukinumab in the treatmentof patients with psoriasis |
| title_fullStr | Experience of using secukinumab in the treatmentof patients with psoriasis |
| title_full_unstemmed | Experience of using secukinumab in the treatmentof patients with psoriasis |
| title_short | Experience of using secukinumab in the treatmentof patients with psoriasis |
| title_sort | experience of using secukinumab in the treatmentof patients with psoriasis |
| topic | psoriasis psoriatic arthritis therapy genetically engineered biological drugs secukinumab |
| url | https://journal.lvrach.ru/jour/article/view/824 |
| work_keys_str_mv | AT nvzilberberg experienceofusingsecukinumabinthetreatmentofpatientswithpsoriasis AT yavkascheeva experienceofusingsecukinumabinthetreatmentofpatientswithpsoriasis AT mmkokhan experienceofusingsecukinumabinthetreatmentofpatientswithpsoriasis |